Jupiter Topco LLC Purchases New Position in 4D Molecular Therapeutics, Inc. $FDMT

Jupiter Topco LLC purchased a new stake in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 5,746,289 shares of the company’s stock, valued at approximately $76,466,000. Jupiter Topco LLC owned 10.99% of 4D Molecular Therapeutics at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of FDMT. Persistent Asset Partners Ltd acquired a new position in shares of 4D Molecular Therapeutics in the 2nd quarter valued at $1,936,000. Dimensional Fund Advisors LP grew its position in 4D Molecular Therapeutics by 77.3% during the first quarter. Dimensional Fund Advisors LP now owns 522,823 shares of the company’s stock valued at $4,863,000 after buying an additional 227,982 shares during the period. Exome Asset Management LLC acquired a new stake in 4D Molecular Therapeutics during the first quarter valued at $1,216,000. Deutsche Bank AG purchased a new position in 4D Molecular Therapeutics in the second quarter valued at $9,456,000. Finally, Perigon Wealth Management LLC purchased a new position in 4D Molecular Therapeutics in the second quarter valued at $1,944,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Price Performance

Shares of NASDAQ FDMT opened at $14.91 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.03 and a current ratio of 8.03. The firm has a fifty day moving average of $12.11 and a 200 day moving average of $10.30. The firm has a market cap of $823.63 million, a PE ratio of -5.67 and a beta of 2.73. 4D Molecular Therapeutics, Inc. has a one year low of $5.97 and a one year high of $16.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, August 13th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). The company had revenue of $3.78 million for the quarter, compared to analysts’ expectations of $3.62 million. 4D Molecular Therapeutics had a negative net margin of 194.74% and a negative return on equity of 41.33%. As a group, research analysts predict that 4D Molecular Therapeutics, Inc. will post -4.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on FDMT shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. B. Riley Financial restated a “buy” rating on shares of 4D Molecular Therapeutics in a research note on Monday, August 17th. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, August 13th. Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen downgraded 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $29.62.

Insider Activity

In related news, insider David Kirn sold 114,746 shares of the firm’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $10.47, for a total value of $1,201,390.62. Following the transaction, the insider directly owned 942,485 shares of the company’s stock, valued at approximately $9,867,817.95. This trade represents a 10.85% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $12.00, for a total value of $117,720.00. Following the completion of the sale, the insider owned 8,617 shares in the company, valued at approximately $103,404. The trade was a 53.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 200,496 shares of company stock valued at $2,240,244. Insiders own 7.90% of the company’s stock.

4D Molecular Therapeutics Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.